Anayama T, Taguchi M, Tatenuma T, Okada H, Miyazaki R, Hirohashi K, Kume M, Matsusaki K, Orihashi K. In-vitro proliferation assay with recycled ascitic cancer cells in malignant pleural mesothelioma: A case report. World J Clin Cases 2019; 7(23): 4036-4043 [PMID: 31832406 DOI: 10.12998/wjcc.v7.i23.4036]
Corresponding Author of This Article
Takashi Anayama, MD, PhD, Associate Professor, Department of Surgery II, Kochi Medical School, Kochi University, 2-5-1akebono-cho, Kochi-shi, Kochi 783-8505, Japan. anayamat@kochi-u.ac.jp
Research Domain of This Article
Oncology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Takashi Anayama, Mai Taguchi, Takehiro Tatenuma, Hironobu Okada, Ryohei Miyazaki, Kentaro Hirohashi, Motohiko Kume, Kazumasa Orihashi, Department of Surgery II, Kochi Medical School, Kochi University, Kochi 783-8505, Japan
Keisuke Matsusaki, Japanese CART Study Group, Kaname Second Clinic, Kanamecho Hospital, Tokyo 171-0043, Japan
Author contributions: Anayama T organized the entire study protocol and mainly wrote the manuscript; Taguchi M and Tatenuma T performed the CD-DST; Okada H and Kume M performed the KM-CART; Miyazaki R, Hirohashi K, and Kume M were responsible for the clinical treatment of the patient; Orihashi K was responsible for the entire study.
Informed consent statement: The patient agreed to all treatments. Every treatment was performed after obtaining written informed consent from the patient.
Conflict-of-interest statement: The authors have no conflicts of interest.
CARE Checklist (2016) statement: The authors have read the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Takashi Anayama, MD, PhD, Associate Professor, Department of Surgery II, Kochi Medical School, Kochi University, 2-5-1akebono-cho, Kochi-shi, Kochi 783-8505, Japan. anayamat@kochi-u.ac.jp
Telephone: +81-88-8802375 Fax: +81-88-8802376
Received: August 13, 2019 Peer-review started: August 13, 2019 First decision: September 23, 2019 Revised: November 8, 2019 Accepted: November 14, 2019 Article in press: November 14, 2019 Published online: December 6, 2019 Processing time: 114 Days and 22 Hours
Abstract
BACKGROUND
We report the first case, to the best of our knowledge, of massive ascites due to recurrent malignant pleural mesothelioma that was controlled using KM-cell-free and concentrated ascites reinfusion therapy (KM-CART). The tumor cells derived via KM-CART were utilized secondarily in an in vitro cell growth assay using the collagen gel droplet-embedded culture drug sensitivity test (CD-DST) to investigate anticancer drug susceptibility.
CASE SUMMARY
A 56-year-old man presented with recurrent malignant mesothelioma with massive ascites; more than 4000 mL of ascitic fluid was removed, filtered, and concentrated using KM-CART, and the cell-free ascitic fluid was reinfused into the patient to improve quality of life. Cancer cells isolated secondarily in an in vitro proliferation assay using CD-DST exhibited low sensitivity to pemetrexed and high sensitivity to gemcitabine. Treatment with gemcitabine maintained stable disease for 4 mo.
CONCLUSION
The combination of KM-CART and CD-DST may be a promising treatment option for malignant ascites associated with malignant mesothelioma.
Core tip: Massive ascites due to recurrent malignant mesothelioma was controlled with innovative cell-free and concentrated ascites reinfusion therapy, and the derived tumor cells were utilized secondarily in an in vitro cell growth assay that contributed to the personalized chemotherapy for the patient.
